Professur für Translationale Frauenheilkunde und Geburtshilfe

The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors (2025) Braun T, Huesmann S, Pfister K, Friedl TW, Hartkopf A, Pantel K, Mehmeti F, et al. Journal article Adherence to digital pregnancy care – lessons learned from the SMART start feasibility study (2025) Jäger K, Nissen M, Leutheuser H, Danzberger N, Titzmann A, Pontones C, Goossens C, et al. Journal article First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer. (2025) Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, et al. Journal article GWAS meta-analysis identifies five susceptibility loci for endometrial cancer (2025) Ramachandran D, Wang X, Laisk T, Zheng Y, Ingold N, Canson DM, Kho PF, et al. Journal article Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis (2025) Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, Köbel M, et al. Journal article Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations (2025) Untch M, Banys-Paluchowski M, Brucker SY, Denkert C, Fasching P, Haidinger R, Harbeck N, et al. Journal article, Review article The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study (2025) Schneeweiss A, Fasching P, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, et al. Journal article Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025) O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article